Introduction
============

Despite the skillful surgical techniques and improvements in combined chemotherapy, ovarian cancer remains the leading cause of death in gynecological malignancies with 5-year survival rates of 44%.[@b1-ott-7-1159] The main reason for poor prognosis of ovarian cancer is that about 70% of the cases are still diagnosed in advanced stages. The majority of advanced patients, including those who achieve a complete response to first-line chemotherapy, will ultimately relapse and do not successfully respond to further treatments.[@b2-ott-7-1159] There is clearly an urgent need to develop new classes of treatment modalities, represented by molecular target-directed therapies.

Glycogen synthase kinase-3 (GSK-3) is a multifunctional serine (Ser)/threonine kinase known to play a pivotal role in the regulation of metabolism, embryonic development, cell differentiation, and apoptosis.[@b3-ott-7-1159],[@b4-ott-7-1159] Two isoforms of GSK-3, GSK-3α and GSK-3β, have been identified with high homology and similar but not identical biochemical functions. The actions of GSK-3 are often regulated by phosphorylation. In opposition to inhibitory regulation by phosphorylation of Ser9 in GSK-3β and Ser21 in GSK-3α, GSK-3 activity is enhanced by phosphorylation of tyrosine (Tyr)216 in GSK-3β and Tyr279 in GSK-3α.[@b4-ott-7-1159] Surprisingly, most of the research so far has primarily focused on GSK-3β only. The dysregulation of GSK-3β has been implicated in tumorigenesis and cancer progression.[@b5-ott-7-1159] It remains controversial whether GSK-3β is a "tumor promoter" or "tumor suppressor".[@b5-ott-7-1159],[@b6-ott-7-1159]

Our interest in GSK-3 stemmed from our previous study in which we found that enhanced expression of GSK-3 is associated with acquired resistance to paclitaxel in ovarian carcinoma cells.[@b7-ott-7-1159] Previous studies have investigated the effect of GSK-3β inhibition in ovarian cancer cells.[@b8-ott-7-1159]--[@b11-ott-7-1159] However, the clinicopathological and biological significance of GSK-3 in ovarian cancer remains inconclusive.

In the present study, we extended the previous study to evaluate the expression status of GSK-3α/β and its actively phosphorylated form, pGSK-3α/β^Tyr279/216^, in ovarian cancer tissues using immunohistochemical analysis.[@b7-ott-7-1159] The associations between clinicopathological factors and expression of GSK-3α/β and pGSK-3α/β^Tyr279/216^ were evaluated. In addition, we provide experimental evidence that GSK-3 inhibition by pharmacological agents or RNA interference can decrease viability of ovarian carcinoma cells and slow tumor growth in vivo.

Materials and methods
=====================

Clinical data and tissue samples
--------------------------------

This study included 71 patients with epithelial ovarian cancer (EOC) who underwent surgical resection followed by paclitaxel/platinum combined chemotherapy in Women's Hospital, School of Medicine, Zhejiang University, in the period 2003 to 2005. The paraffin-embedded specimens were retrieved from the archives of the Department of Pathology of our hospital. Meanwhile, we also collected 20 samples of benign ovarian tumor (ten serous and ten mucinous cystadenoma) as controls. The use of all tissues has been approved by the Ethics Committee of Women's Hospital, School of Medicine, Zhejiang University (No 20100009). Because the use of redundant paraffin-embedded specimens did not bring any damage to patients, the Ethics Committee waived the need for consent from the patients. All patients with EOC were followed-up two to four times annually until December 2010. The following data were collected: age, date of diagnosis, date of relapse, date of last follow-up, date and cause of death, serum cancer antigen 125 (CA125) values, International Federation of Gynecology and Obstetrics (FIGO) stage, histologic type and grade, residual tumor mass, and response to chemotherapy. Chemotherapeutic response was evaluated according to the Response Evaluation Criteria in Solid Tumors (RECIST).[@b12-ott-7-1159] Patients achieving complete response or partial response to treatment were considered as responders, and patients achieving progressive disease or stable disease were considered as nonresponders.

Immunohistochemistry
--------------------

Expression of GSK-3α/β and pGSK-3α/β^Tyr279/216^ in tissues was examined immunohistochemically by the avidin--biotin-- peroxidase complex method following microwave antigen retrieval of paraffin sections, using a mouse monoclonal antibody to human GSK-3α/β (diluted 1:30; Santa Cruz Biotechnology Inc., Dallas, TX, USA) and a rabbit polyclonal antibody to human pGSK-3α/β^Tyr279/216^ (diluted 1:80; Santa Cruz Biotechnology), respectively. The expression levels of GSK-3α/β and pGSK-3α/β^Tyr279/216^ were determined semi-quantitatively according to the described method.[@b13-ott-7-1159] Briefly, the percentage of positive cells was rated as follows: 0 points, 0% to 25%; 1 point, 26% to 50%; 2 points, 51% to 75%; 3 points, \>75%. The staining intensity was rated as follows: 0 points, no staining; 1 point, weak intensity; 2 points, moderate intensity; 3 points, strong intensity. Points for expression intensity and percentage of positive cells were added (total score of 0--6). Thus, the score 0 was taken as negative (−); 1 to 2 as weak positive (+); 3 to 4 as moderate positive (++); and 5 to 6 as strong positive (+++).

Cell culture and reagents
-------------------------

Human ovarian carcinoma cell line SKOV3 was obtained from the American Type Culture Collection (Manassas, VA, USA) and maintained in McCoy's 5A medium (Gibco^®^; Thermo Fisher Scientific, Waltham, MA, USA), supplemented with 10% fetal bovine serum (FBS), 100 U/mL penicillin, and 100 μg/mL streptomycin at 37°C and 5% CO~2~. Paclitaxel-resistant cell subline, SKOV3-TR30, was developed by exposing parental SKOV3 cells to increased concentration of paclitaxel as described previously.[@b14-ott-7-1159] Two GSK-3 inhibitors, lithium chloride (LiCl) and 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione (TDZD-8), were purchased from Sigma-Aldrich (St Louis, MO, USA).

Cell viability assay
--------------------

The effect of LiCl and TDZD-8 on cell viability was determined by 3-(4,5- dimethylthiazol-2-yl)-2,5-diphenyltetrazo-lium bromide (MTT) assay as described previously.[@b14-ott-7-1159] Briefly, 2,000 cells per well were seeded in 96-well plates, incubated in a CO~2~ incubator overnight at 37°C, and then treated with different doses of LiCl (0--80 mM) and TDZD-8 (0--20 μM) in triplicate for indicated times. A volume of 10 μL of MTT (5 mg/mL) was added to the cells and incubated at 37°C for 3 hours. The MTT solution was removed and 200 μL of dimethyl sulfoxide was added to each well to dissolve the blue formazan crystals. The optical density was measured at 490 nm wavelength using a Universal microplate reader Elx800 (BIO-TEK, Winooski, VT, USA). The absorbance values were normalized by assigning the value of the control line in the medium without drug to 1.0 and the value of the no-cell control to 0. Mean values were calculated from three independent experiments.

RNA interference
----------------

Small interfering RNA (siRNA) specific to human GSK3α (GSK-3α siRNA \[h\] sc-29339) and GSK3β (GSK-3β siRNA \[h\] sc-35527) were purchased from Santa Cruz Biotechnology. Unrelated control siRNA (sc-37007; Santa Cruz Biotechnology) was also used. Transfection was carried out using DharmaFECT siRNA transfection reagents (Thermo Fisher Scientific) according to the manufacturer's recommendations. Briefly, 24 hours after plating, cells were incubated with the siRNA/DharmaFECT complexes at the appropriate concentration (70 nM for GSK3α, 50 nM for GSK3β) in antibiotic- and serum-free medium for 6 hours at 37°C. After this incubation period, transfection medium was replaced with fresh medium containing FBS. The effect of siRNA on protein expression was determined by Western immunoblotting, and the relative cell viability was determined by MTT assay 72 hours after transfection.

Western blotting
----------------

Cells were harvested and lysed in modified protein lysis buffer (50 mM Tris-HCl, pH 8.0, 150 mM NaCl, 0.1% sodium dodecyl sulfate \[SDS\], 1% NP-40, 0.02% sodium azide) added with 1% proteinase inhibitor cocktail (Sigma-Aldrich). The protein concentration was measured by the Bradford method.[@b15-ott-7-1159] Equal amounts of sample lysates were separated by SDS-PAGE and electrophoretically transferred onto a nitrocellulose membrane. The membrane was blocked with 5% nonfat dried milk in TBST buffer (20 mM Tri-HCl, pH 7.4, 150 mM NaCl, and 0.1% Tween-20) and incubated overnight at 4°C with the antibodies against GSK-3α/β (1:500 mouse monoclonal antibody) and β-actin (1:1,000 mouse monoclonal antibody; Santa Cruz Biotechnology), respectively. The membrane was washed with TBST buffer and incubated with appropriate secondary antibodies. The protein bands were visualized using the enhanced Pierce chemiluminescence kits (Thermo Fisher Scientific). Signal data was normalized for β-actin bands, and a mean value was calculated from three independent experiments.

Nude mice and xenografts
------------------------

Eight female BALB/c-nude mice, aged 4--5 weeks, were purchased from Shanghai Laboratory Animal Center (Shanghai, People's Republic of China) and housed within a dedicated specific pathogen-free facility at the Laboratory Animal Center of Zhejiang University. To develop the tumor xenografts, 5×10^6^ SKOV3 cells (in 0.2 mL PBS) were injected subcutaneously near the axillary fossa of nude mice. Once tumors were palpable, mice were randomly divided into two groups (four mice per group) and treated with various regimens: normal saline control or LiCl. LiCl (340 mg/kg, intraperitoneally) or normal saline were injected every 2 days for a total of seven treatments (day 1, 3, 5, 7, 9, 11, 13). Length (l) and width (w) of tumors were measured with a vernier caliper once a week, and the tumor volumes were calculated using the formula, $$0.52 \times 1 \times w^{\text{2}}.$$

At the end of the study (7 weeks after drug treatment), animals were sacrificed according to the protocol developed by the Guidance of the Animal Center, and tumors were excised and weighed.

Statistical analysis
--------------------

The data were compiled with the software package SPSS, version 16.0 (Chicago, IL, USA). Mann--Whitney *U* tests were used to assess the correlation between clinicopathological parameters and expressions of GSK-3α/β and pGSK-3α/β^Tyr279/216^. Univariate survival analysis was performed by the Kaplan--Meier method (log-rank test). The multivariate survival analysis was performed according to the Cox regression model. Differences in data among treatment groups in experiments in vitro and in vivo were analyzed using one-way analysis of variance (ANOVA). All tests were two-tailed, and *P*\<0.05 was considered to be significant.

Results
=======

Increased expression of GSK-3α/β and pGSK-3α/β^Tyr279/216^ in ovarian cancer tissues
------------------------------------------------------------------------------------

Using immunohistochemistry, we investigated the expression of GSK-3α/β and pGSK-3α/β^Tyr279/216^ in specimens of EOC and benign tumors. [Figures 1](#f1-ott-7-1159){ref-type="fig"} and [2](#f2-ott-7-1159){ref-type="fig"} show the representative features of immunohistochemical staining of GSK-3α/β and pGSK-3α/β^Tyr279/216^, respectively. The expression levels of GSK-3α/β and pGSK-3α/β^Tyr279/216^ in EOC were significantly higher than those in benign tumors (*P*\<0.001) ([Tables 1](#t1-ott-7-1159){ref-type="table"} and [2](#t2-ott-7-1159){ref-type="table"}). Moreover, a significant correlation between expression of GSK-3α/β and pGSK-3α/β^Tyr279/216^ was observed (*r*=0.278, *P*=0.019). Thus, it is likely that overexpression and aberrant activation of GSK-3 is a pathologic characteristic of clinical ovarian cancer.

In patients with EOC, the clinicopathologic and prognostic significance of expression levels of GSK-3α/β and pGSK-3α/β^Tyr279/216^ were also analyzed. High expression of GSK-3α/β was more likely to be found in EOC patients with advanced FIGO stages (*P*=0.001) and high serum CA125 (*P*=0.040) ([Table 1](#t1-ott-7-1159){ref-type="table"}). Higher expression of pGSK-3α/β^Tyr279/216^ was more prevalent in tissues from patients with advanced FIGO stages (*P*=0.004), residual tumor mass (*P*=0.044), high serum CA125 (*P*=0.003), and poor chemoresponse (*P*=0.001) ([Table 2](#t2-ott-7-1159){ref-type="table"}). Until the final follow-up time, the median follow-up time of the total 71 patients was 59 months (range 5--87). Worse overall survival was revealed by Kaplan-- Meier survival curves in patients with high expression of GSK-3α/β (*P*=0.004) or pGSK-3α/β^Tyr279/216^ (*P*=0.005) ([Figure 3](#f3-ott-7-1159){ref-type="fig"}). Multivariate analysis indicated that FIGO stage (hazard ratio \[HR\] =11.1, *P*=0.02), GSK-3α/β expression (HR =3.1, *P*=0.045), and pGSK-3α/β^Tyr279/216^ expression (HR =2.8, *P*=0.041) were independent prognostic factors for overall survival.

Inhibition of GSK-3 decreases viability of ovarian carcinoma cells
------------------------------------------------------------------

The immunohistochemical results in our study indicate that GSK-3 has a putative pathologic role in ovarian carcinoma. To determine whether active GSK-3 is essential for survival of ovarian carcinoma cells, we tested the effect of two GSK-3 inhibitors, LiCl and TDZD-8, in SKOV3 and SKOV3-TR30, a paclitaxel-resistant cell subline derived from SKOV3. We found that both LiCl and TDZD-8 can decrease cell viability of SKOV3 and SKOV3-TR30 ([Figure 4A--D](#f4-ott-7-1159){ref-type="fig"}).

To determine whether the reduction of cell viability by pharmacological inhibition of GSK-3 was specific to GSK-3 isoforms, we depleted the expression of GSK-3α or GSK-3β in SKOV3 and SKOV3-TR30 cells using RNA interference. Following a 3-day exposure to GSK-3-specific siRNAs, immunoblotting showed ≥70% reduction in expression levels of the corresponding GSK-3 isoforms when compared to untransfected or scrambled siRNA transfected controls ([Figure 4E](#f4-ott-7-1159){ref-type="fig"}). We found that depletion of either GSK-3α or β isoforms can significantly decrease cell viability of ovarian cancer ([Figure 4F](#f4-ott-7-1159){ref-type="fig"}). These results indicate that both GSK-3 isoforms may contribute to regulate cell viability of ovarian carcinoma.

Effect of LiCl on tumor growth in vivo
--------------------------------------

To determine whether GSK-3 inhibition affects ovarian tumor growth in vivo, we used a xenograft model of ovarian cancer generated by SKOV3 cells. As shown in [Figure 5A](#f5-ott-7-1159){ref-type="fig"}, tumor growth was slowed in the LiCl group as measured by calculated tumor volume. The differences between the control and LiCl-treated tumor volumes at days 21, 28, and 35 were statistically significant. By the end of the study, the differences of tumor volumes between control and treatment group were statistically insignificant ([Figure 5A and B](#f5-ott-7-1159){ref-type="fig"}). However, tumor growth was significantly reduced in the LiCl group as measured by tumor weight when tumors were excised at the end of the study ([Figure 5C](#f5-ott-7-1159){ref-type="fig"}).

Discussion
==========

In view of the known biological importance of GSK-3 in human cancers and the unknown clinicopathological significance of GSK-3 expression in ovarian carcinoma, we used immunohistochemistry to assess the expression status of GSK-3α/β and its actively phosphorylated form, pGSK-3α/β^Tyr279/216^, in a series of 71 EOC. In this study, we performed immunohistochemical analysis using two antibodies which can simultaneously recognize GSK-3α and GSK-3β and the activated form of GSK-3α and GSK-3β, respectively. We found that the expression levels of GSK-3α/β and pGSK-3α/β^Tyr279/216^ in EOC were significantly higher than those in benign ovarian tumors. High expressions (++ − +++) of GSK-3α/β were observed in 59.2% (42/71) of the EOC samples, which correlated with advanced FIGO stage and high serum CA125. High expressions (++− +++) of pGSK-3α/β^Tyr279/216^ were observed in 53.5% (38/71) of EOC, which associated with advanced FIGO stage, postoperative residual tumor mass, and high serum CA125. These findings reflect that expression of GSK-3α/β and pGSK-3α/β^Tyr279/216^ seem to increase with tumor growth and invasiveness, and the aberrant activation of GSK-3α/β may play a role in the progression of EOC. Consistently, Do et al found that pGSK-3α/β^Ser9/21^ immunostaining in benign neoplasias was significantly higher than in ovarian carcinomas.[@b16-ott-7-1159] Loss of pGSK-3α/β^Ser9/21^ immunoreactivity indirectly indicates upregulation of GSK-3 activity, despite having not detected pGSK-3α/β^Tyr279/216^ immunostaining.

EOC is mainly treated by paclitaxel/platinum combined chemotherapy, and this study has evaluated the expression of GSK-3α/β or pGSK-3α/β^Tyr279/216^ as a marker of chemotherapeutic responsiveness in such patients. In our study, 77.5% (55/71) of EOC patients showed a response to the combined chemotherapy, and no correlation was observed between GSK-3α/β expression and chemotherapeutic responsiveness. However, we found that expressions of pGSK-3α/β^Tyr279/216^ were clearly lower in responders than those in nonresponders. The response rate (30/33) in patients with low expression (− − +) of pGSK-3α/β^Tyr279/216^ was increased significantly. These data strongly suggest that the expression level of activated GSK-3 in ovarian cancer is inversely associated with responsiveness of paclitaxel/platinum chemotherapy. High expression of pGSK-3α/β^Tyr279/216^ in cancer tissue may be a potential predictor for primary resistance to the first-line chemotherapy. Our results are inconsistent with the report by Cai et al,[@b9-ott-7-1159] who demonstrated that GSK-3β inhibition may confer resistance to cisplatin in the A2780 ovarian carcinoma cell line in vitro. However, their results came from only one cell model, without verification of clinical samples. It cannot be excluded that GSK-3 may play a different role in different ovarian cancer cells.

There have been a number of conflicting reports concerning the prognostic values of GSK-3β in human cancers.[@b17-ott-7-1159]--[@b23-ott-7-1159] In the present study, we found that high expressions of GSK-3α/β and pGSK-3α/β^Tyr279/216^ were significantly associated with shortened overall survival in patients with EOC. It gave us a clue that overexpression and aberrant activation of GSK-3 might be potential independent predictors for poor prognosis in ovarian cancer. Our results agreed with previous results shown in lung cancer[@b18-ott-7-1159] and bladder cancer.[@b22-ott-7-1159] Nevertheless, the current results do not agree with those in tongue cancer,[@b17-ott-7-1159] breast cancer,[@b19-ott-7-1159],[@b20-ott-7-1159] gastric cancer,[@b21-ott-7-1159] and lymphoma.[@b23-ott-7-1159] Previous studies indicated that the biological significance of GSK-3 activation or inactivation appears to be cell-type specific. In cancers of the pancreas,[@b24-ott-7-1159] colon,[@b25-ott-7-1159] ovary,[@b8-ott-7-1159] and osteosarcoma,[@b26-ott-7-1159] GSK-3β activity is believed to promote cell survival or tumor growth. Additionally, cell proliferation and survival were attenuated by inhibiting the activity of GSK-3β in myeloma,[@b27-ott-7-1159] thyroid cancer,[@b28-ott-7-1159] leukemia,[@b29-ott-7-1159] glioma,[@b30-ott-7-1159],[@b31-ott-7-1159] renal cancer,[@b32-ott-7-1159] gastrointestinal cancer,[@b33-ott-7-1159] and bladder cancer[@b22-ott-7-1159] cells. Moreover, GSK-3 inhibition may enhance the antitumor effect of TNF-related apoptosis-inducing ligand (TRAIL) in pancreatic cancer cells or sorafenib in renal cell carcinoma.[@b34-ott-7-1159],[@b35-ott-7-1159] Inconsistently, GSK-3β seems to be a "tumor suppressor" or "proapoptotic protein" in other cancer cells, such as hepatoma[@b36-ott-7-1159],[@b37-ott-7-1159] and breast cancer[@b38-ott-7-1159] cells. Considering the biologic complexity of GSK-3 in various normal cellular functions and the pathogenesis of various cancers, we believe that this discrepancy is not surprising.

Recently, Cao et al[@b8-ott-7-1159] and Hilliard et al[@b10-ott-7-1159] showed GSK-3 as a potential therapeutic target in ovarian cancer. Nevertheless, the biological significance of GSK-3 in paclitaxel-resistant ovarian cancer cells has not been evaluated. Our study revealed that pharmacological inhibitors of GSK-3 can reduce viability of SKOV3 and SKOV3-TR30 cells, a paclitaxel-resistant cell subline derived from SKOV3. We also found that genetic depletion of either GSK-3α or β isoforms can significantly decrease viability of paclitaxel-sensitive and -resistant ovarian carcinoma cells. Although most of the previous studies have not focused on the significance of GSK-3α, a role for GSK-3α in acute myeloid leukemia has been demonstrated.[@b39-ott-7-1159] Our results indicate that both GSK-3 isoforms may contribute to regulate cell viability in ovarian carcinoma.

To validate the in vitro findings of growth inhibition in an in vivo situation, nude mice were implanted with SKOV3 cells. The dose of LiCl was chosen based on previous reports evaluating subcutaneously grafted thyroid cancers.[@b28-ott-7-1159] Our study showed that treatment of LiCl in mice bearing tumor xenograft could significantly slow tumor growth compared with the saline control. This finding was in agreement with a previous study, although Cao et al mixed LiCl and tumor cells together before subcutaneous injection.[@b8-ott-7-1159] The safety of lithium ions has been established as a result of its use in the treatment of psychotic diseases for over 60 years. Thus, the possibility that LiCl could be a viable treatment for ovarian cancer is exciting.

In summary, we have shown that overexpression and aberrant activation of GSK-3 may contribute to progression of ovarian cancer and have a potential role as independent prognostic factors in EOC patients, and that inhibition of GSK-3 may be a potential therapy for ovarian cancer. Further studies are warranted to confirm and expand these findings, including screening more reasonable administration schedules of GSK-3 inhibitor/chemotherapy combination.
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![Representative features of immunohistochemical staining of GSK-3α/β.\
**Notes:** Little staining of GSK-3α/β in benign epithelial ovarian tumor (200×) (**A**) and (400×) (**B**); EOC case with low expression of GSK-3α/β (200×) (**C**) and (400×) (**D**); EOC case with high expression of GSK-3α/β (200×) (**E**) and (400×) (**F**).\
**Abbreviations:** EOC, epithelial ovarian cancer; GSK, glycogen synthase kinase.](ott-7-1159Fig1){#f1-ott-7-1159}

![Representative features of immunohistochemical staining of pGSK-3α/β^Tyr279/216^.\
**Notes:** Little staining of pGSK-3α/β^Tyr279/216^ in benign epithelial ovarian tumor (200×) (**A**) and (400×) (**B**); EOC case with low expression of pGSK-3α/β^Tyr279/216^ (200×) (**C**) and (400×) (**D**); EOC case with high expression of pGSK-3α/β^Tyr279/216^ (200×) (**E**) and (400×) (**F**).\
**Abbreviations:** EOC, epithelial ovarian cancer; GSK, glycogen synthase kinase.](ott-7-1159Fig2){#f2-ott-7-1159}

![Kaplan--Meier survival analysis among 71 patients with epithelial ovarian cancer according to expression of GSK-3α/β and pGSK-3α/β^Tyr279/216^.\
**Notes:** Patients with high expression (++ − +++) of GSK-3α/β (**A**) or pGSK-3α/β^Tyr279/216^ (**B**) had a significantly inferior overall survival time than those with low expression (*P*=0.004, *P*=0.005, respectively).\
**Abbreviation:** GSK, glycogen synthase kinase.](ott-7-1159Fig3){#f3-ott-7-1159}

![Effect of GSK-3 inhibition on cell viability.\
**Notes:** LiCl (**A** and **B**) and TDZD-8 (**C** and **D**) reduces viability of ovarian carcinoma cells; SKOV3 (**A** and **C**) and SKOV3-TR30 (**B** and **D**) cells were treated with various concentrations of LiCl or TDZD-8, and cell viability was determined using the MTT assay at 24, 48, and 72 hours; Data represent the mean of three different experiments with triplicate wells; To determine GSK-3α/β protein levels after siRNA treatment, protein extracts were obtained using a lysis buffer containing protease inhibitors cocktail 72 hours posttransfection and analyzed by Western blot (**E**); A reduction of ≥70% in the expression levels of the corresponding GSK-3 isoforms was observed when compared to untransfected or scrambled siRNA transfected controls. GSK-3 silencing decreases viability of ovarian carcinoma cells (**F**); Cell viability was determined by MTT assay 72 hours after transfection with GSK-3α siRNA (70 nM), GSK-3β siRNA (50 nM), or both in SKOV3 and SKOV3-TR30 cells; Data represent the mean of three different experiments with triplicate wells. \**P*\<0.05, ^\#^*P*\<0.01 compared with control siRNA.\
**Abbreviations:** GSK, glycogen synthase kinase; LiCl, lithium chloride; MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide; siRNA, small interfering RNA; TDZD-8, 4-benzyl-2-methyl-1,2,4-thiadiazolidine-3,5-dione.](ott-7-1159Fig4){#f4-ott-7-1159}

![In vivo validation of tumor growth inhibition by LiCl treatment.\
**Notes:** After palpable tumors generated by SKOV3 cells developed, ip injections of LiCl (340 mg/kg) were done every 2 days for a total of seven treatments, the tumors were measured, and the tumor volume was calculated once a week (**A**); The growth of the LiCl-treated tumors was slowed compared with the control; Data are means ± SD (n=4); \**P*\<0.05, ^\#^*P*\<0.01 versus control; Tumor specimens dissected from the nude mice xenografted with SKOV3 cells at the end of the study (**B**); Comparison of tumor weight between LiCl group and control (**C**); Data are means ± SD (n=4); \**P*,0.05 versus control.\
**Abbreviations:** ip, intraperitoneal; LiCl, lithium chloride; SD, standard deviation.](ott-7-1159Fig5){#f5-ott-7-1159}

###### 

Expression of GSK-3α/β in epithelial ovarian cancer and benign ovarian tumor

  Parameters                          GSK-3α/β immunostaining   *z*   *P*-value                 
  ----------------------------------- ------------------------- ----- ----------- ---- -------- ---------
  Benign or malignant                                                                  −5.956   \<0.001
   Benign tumor (n=20)                18                        2     0           0             
   EOC (n=71)                         8                         21    19          23            
  Age of EOC patient (years)                                                           −0.222   0.824
   ≤50 (n=38)                         3                         13    11          11            
   \>50 (n=33)                        5                         8     8           12            
  Stage of EOC                                                                         −3.328   0.001
   FIGO I + II (n=27)                 5                         11    9           2             
   FIGO III + IV (n=44)               3                         10    10          21            
  Residual tumor of EOC                                                                −1.406   0.160
   ≤1 cm (n=53)                       8                         15    15          15            
   \>1 cm (n=18)                      0                         6     4           8             
  Histological type of EOC                                                             −0.078   0.938
   Serous (n=39)                      3                         14    9           13            
   Other (n=32)                       5                         7     10          10            
  Histological grade of EOC                                                            −1.552   0.121
   Grade 1 (n=11)                     1                         5     5           0             
   Grade 2 + 3 (n=60)                 7                         16    14          23            
  Serum CA125 of EOC patient (U/mL)                                                    −2.053   0.040
   ≤500 (n=47)                        8                         15    11          13            
   \>500 (n=24)                       0                         6     8           10            
  Chemotherapy response of EOC                                                         −1.234   0.217
   Response (n=55)                    6                         19    14          16            
   Nonresponse (n=16)                 2                         2     5           7             

**Abbreviations:** CA125, cancer antigen 125; EOC, epithelial ovarian cancer; FIGO, International Federation of Gynecology and Obstetrics; GSK, glycogen synthase kinase.

###### 

Expression of pGSK-3α/β^Tyr279/216^ in epithelial ovarian cancer and benign ovarian tumor

  Parameters                          pGSK-3α/β^Tyr279/216^ immunostaining   *z*   *P*-value                 
  ----------------------------------- -------------------------------------- ----- ----------- ---- -------- ---------
  Benign or malignant                                                                               −4.759   \<0.001
   Benign tumor (n=20)                16                                     2     1           1             
   EOC (n=71)                         11                                     22    14          24            
  Age of EOC patient (years)                                                                        −0.685   0.508
   ≤50 (n=38)                         8                                      10    8           12            
   \>50 (n=33)                        3                                      12    6           12            
  Stage of EOC                                                                                      −2.815   0.004
   FIGO I + II (n=27)                 5                                      13    6           3             
   FIGO III + IV (n=44)               6                                      9     8           21            
  Residual tumor of EOC                                                                             −2.005   0.044
   ≤1 cm (n=53)                       10                                     18    10          15            
   \>1 cm (n=18)                      1                                      4     4           9             
  Histological type of EOC                                                                          −1.518   0.132
   Serous (n=39)                      5                                      9     10          15            
   Other (n=32)                       6                                      13    4           9             
  Histological grade of EOC                                                                         −0.298   0.791
   Grade 1 (n=11)                     1                                      5     2           3             
   Grade 2 + 3 (n=60)                 10                                     17    12          21            
  Serum CA125 of EOC patient (U/mL)                                                                 −2.920   0.003
   ≤500 (n=47)                        10                                     17    9           11            
   \>500 (n=24)                       1                                      5     5           13            
  Chemotherapy response of EOC                                                                      −3.292   0.001
   Response (n=55)                    10                                     20    13          12            
   Nonresponse (n=16)                 1                                      2     1           12            

**Abbreviations:** CA125, cancer antigen 125; EOC, epithelial ovarian cancer; FIGO, International Federation of Gynecology and Obstetrics; GSK, glycogen synthase kinase.
